Manufactured under cleanroom environments with full batch traceability, compliant with USP monograph standards and validated for immediate deployment across Turkish health networks.
An in-depth analysis of high-purity Oxidized Regenerated Cellulose (ORC), manufacturing chain of custody, and regulatory compliance for medical device importers across Istanbul, Ankara, and Izmir.
Oxidized Regenerated Cellulose (ORC) reacts with capillary blood to form a dark, gel-like matrix within 2 to 4 minutes, stabilizing clot formation without swelling or tissue displacement.
The acidic local microenvironment (pH < 4.0) created by ORC degradation exerts a broad-spectrum bactericidal effect against MRSA, MRSE, and Gram-negative pathogens common in hospital settings.
Complete technical documentation packages including Declaration of Conformity, CE 2017/745 MDR dossiers, and ISO 13485:2016 certificates formatted specifically for Ministry of Health (ÜTS) registration.
Surgical intraoperative bleeding management is a critical determinant of patient outcomes, surgical duration, and postoperative recovery speed. Absorbable hemostatic agents derived from Oxidized Regenerated Cellulose (ORC) serve as an essential adjunct when conventional hemostatic measures such as suturing, electrocautery, or ligation are impractical or ineffective.
Unlike standard collagen or gelatin-based sponges, advanced ORC hemostatic gauze is produced through a controlled chemical oxidation of continuous alpha-cellulose fibers. This process converts primary hydroxyl groups into carboxylic acid functions, resulting in a biocompatible, poly-anionic polymer structure. When placed in contact with active parenchymal or venous oozing, the ORC matrix absorbs fluid, swells into a cohesive gelatinous mass, and acts as an artificial clot scaffold. Platelets adhere to the fibrous matrix, accelerating the physiological coagulation cascade independently of the patient's systemic clotting factors.
Furthermore, complete absorption occurs hydrolytically within 7 to 14 days without eliciting granulomatous tissue reactions or fibrous capsule formation. This rapid bioresorption profile makes ORC hemostats the reference standard for cardiovascular, neurological, gynecological, and general laparoscopic procedures across leading healthcare institutions worldwide.
Procurement teams in Turkish hospitals must evaluate multiple parameters when selecting hemostatic matrices. Below is a structural comparison between high-purity ORC hemostats and traditional alternatives:
| Hemostatic Material | Mechanism of Action | Absorption Time | Antimicrobial Property | Tissue Reaction | Storage & Handling |
|---|---|---|---|---|---|
| Oxidized Regenerated Cellulose (ORC) | Physical gel scaffold + platelet entrapment | 7 – 14 Days | Yes (Low pH bactericidal) | Minimal / Negligible | Ambient (15-30°C), Ready-to-use |
| Purified Gelatin Sponge | Porous liquid absorption + physical barrier | 4 – 6 Weeks | No | Moderate granulomatous risk | Requires pre-moistening |
| Microfibrillar Collagen | Direct platelet aggregation activation | 8 – 12 Weeks | No | Potential adhesion formation | Moisture sensitive, sticky |
| Fibrin Sealants / Thrombin Matrix | Enzymatic fibrin clot formation | 2 – 4 Weeks | No | Immunogenic potential | Cold chain required (-20°C) |
Turkey’s medical device market is undergoing rapid transformation, driven by the expansion of large-scale City Hospitals (T.C. Sağlık Bakanlığı Şehir Hastaneleri), an increasing volume of complex surgeries, and Turkey's position as a premier global destination for health tourism. Private hospital networks such as Acıbadem Healthcare Group, Memorial Health Group, and Medical Park demand premium-grade surgical consumables that meet stringent international standards while offering cost efficiencies over dominant Western brands.
Because Turkey operates under the EU-Turkey Customs Union agreement, medical device imports must fully harmonize with European Union Medical Device Regulation (EU MDR 2017/745). All hemostats and surgical sutures entering the Turkish market must be registered in the centralized Ürün Takip Sistemi (ÜTS) database administered by the Turkish Medicines and Medical Devices Agency (TİTCK). OEM/ODM factories serving this region must possess flawless technical dossiers, ISO 13485 certification, and legalizable Free Sale Certificates (FSC) to facilitate smooth customs clearance through major logistics hubs including Istanbul Ambarlı, Mersin, and Izmir ports.
Our manufacturing facility operates under an integrated single-site model. From initial rayon polymer conversion to knitting, chemical oxidation, micro-slitting, precision needle swaging, and validated Ethylene Oxide (EO) sterilization, every stage is contained within certified ISO Class 7 and Class 8 cleanroom environments.
Quality assurance is embedded in each batch workflow:
We empower Turkish medical brands, tender agents, and hospital supply chains with customized packaging, dual-language artwork, and flexible batch volumes.
Select from standard woven gauze (5x7.5 cm, 10x20 cm), high-density heavy knitted matrices, or non-woven fibrillar structures designed for specific surgical specialties.
In-house artwork team ensures compliant product primary foil, outer carton box, and IFU design featuring Turkish translations, UDI / GS1 barcodes, and symbol standardization.
Receive complete technical files (STED format), biocompatibility test results (ISO 10993 series), clinical evaluations, and notarized FSCs for fast ÜTS system approval.
Direct answers to technical, commercial, and regulatory queries from Turkish medical distributors and hospital purchasing managers.
Request product samples, technical dossiers for ÜTS registration, or custom OEM price quotes directly from our export engineering desk.
